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Abstract 
Adrenal myelolipomas are rare benign tumors of the adrenal cortex composed of adipose 
and hematopoietic cells. They have been postulated to arise from repeated stimulation by 
stress, inflammation and ACTH oversecretion. Myelolipomas are usually detected incidentally 
on imaging and do not require any active intervention besides regular follow-up by imaging. 
However,  myelolipomas  may  insidiously  grow  to  large  sizes  and  cause  mass  effects  and 
hemorrhage. Timely diagnosis and surgical resection are curative and lifesaving. 
© 2014 S. Karger AG, Basel 
Introduction 
Adrenal myelolipomas are benign tumors which are usually asymptomatic and diag-
nosed incidentally on imaging or during autopsy. They were first described by Gierke in 
1905 and were termed as myelolipomas by Oberling in 1929 [1, 2]. They are uncommon 
benign tumors of the adrenal cortex constituting approximately for 3–5% of all primary 
adrenal tumors and are increasingly being diagnosed due to improved imaging techniques 
[3, 4]. Adrenal myelolipomas are most frequently detected after the fifth decade and are seen 
almost  equally  in  both  genders.  They  are  commonly  found  as  unilateral  masses,  but 
occasional  bilateral  masses  have  been  documented  [5].  A  right-sided  predominance  in  
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unilateral tumors has also been reported [6]. They are usually asymptomatic but myeloli-
pomas may attain large sizes and present as abdominal masses [7, 8]. Patients may also 
present with symptoms of hematuria and hypertension [9]. Their size may also cause mass 
effect by compressing other intra-abdominal organs [10]. Malignant transformation has not 
been documented  in  these tumors.  Diagnosis  of  giant  adrenal  myelolipomas  in  a timely 
manner may prevent complications due to hemorrhage and can be lifesaving. 
Case Description 
A 52-year-old man with a past medical history significant for atrial fibrillation, diabetes 
type 2 and hypertension for 30 years was admitted with early satiety for the past 3 months 
and progressive dyspnea on exertion for 3 weeks. He also complained of gradual uninten-
tional weight loss of approximately 100 pounds over the last 10 years. He had been a non-
smoker and a moderate alcohol user for the last 30 years. On initial presentation to the 
hospital, he denied shortness of breath at rest or chest discomfort and was in no acute 
distress.  
His blood pressure was 204/93 mm Hg on the left arm and 194/88 mm Hg on the right 
arm with an irregular heart rate of 54 beats/min and oxygen saturation of 96% on room air. 
The lungs were clear to auscultation, jugular venous distension was noted at 13 cm above 
the sternal angle and 3+ bilateral leg edema with scrotal edema. Cardiac auscultation was 
pertinent for 3/6 systolic ejection murmur over the left sternal border. His abdomen felt 
firm and lacking in tympanicity, but it was non-tender in all four quadrants. Bowel sounds 
were audible but faint. Laboratory values were notable for a brain natriuretic peptide of 980 
ng/l, creatinine of 1.2 mg/dl, BUN of 20 mg/dl, HCO3 of 31 mEq/l, INR of 1.23, Hb of 12.5 
g/dl, Na of 140 mEq/l, K of 3.7 mEq/l and negative cardiac troponins. He was monitored in 
the Intensive Care Unit for decompensated heart failure with uncontrolled hypertension.  
To promote diuresis and reduce afterload, he was administered intravenous furosemide 
80 mg, oral metolazone 2.5 mg, oral hydralazine 75 mg every 6 h, oral clonidine 0.3 mg, 
lisinopril 40 mg, isosorbide mononitrate 120 mg and losartan 100 mg. Overnight, he had an 
episode of moderate self-limited epistaxis with minimal  improvement  in blood  pressure 
control.  He  remained  in  slow  atrial  fibrillation  with  a  lowest  recorded  heart  rate  of  38 
beats/min. However, he denied dizziness at any time despite a negative fluid balance of 1.8 
liters. Renal function worsened with an increase of creatinine to 1.6 mg/dl. 
An  echocardiogram  showed  a  left  ventricular  ejection  fraction  of  30%  with  four-
chamber dilatation, moderately reduced  right  ventricular systolic function, severe mitral 
regurgitation and moderate pulmonary hypertension. He underwent right heart catheteriza-
tion  showing  a  right  atrial  pressure  of  12  mm  Hg,  right  ventricular  pressure  (systol-
ic/diastolic) of 60/12 mm Hg, pulmonary artery pressure of 60/23 mm Hg and pulmonary 
capillary wedge pressure of 20 mm Hg and a cardiac index of 2.3 liters/min. A left heart 
catheterization revealed clean coronaries, and alcohol was thought to be the likely etiology 
of non-ischemic cardiomyopathy in this patient. Urine catecholamine and vanillylmandelic 
acid  were  measured  and  a  magnetic  resonance  angiography  of  the  renal  arteries  was 
performed to evaluate for secondary causes of hypertension. This showed non-obstructed 
renal arteries bilaterally.  
A minimally enhancing 22 × 16 × 23 cm mass was visualized in the left upper and mid-
abdomen displacing the spleen and stomach posterosuperiorly, the pancreas anteriorly and 
the left kidney inferiorly (fig. 1b). The left adrenal gland was not visible. A contrast-enhanced 
CT  scan  of  the  abdomen  to  further  characterize  the  mass  showed  no  infiltration  of  the  
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surrounding vasculature or organs, and the left adrenal gland was visualized although it 
could not be confirmed if the mass was arising from the adrenals (fig. 1a). The suggested 
radiological differential diagnoses were: liposarcoma, teratoma and myelolipoma. A needle 
biopsy  of  this  mass  showed  adipose  tissue  with  foci  of  extramedullary  hematopoiesis 
consistent with myelolipoma without any evidence of malignancy, confirming this mass to 
be a benign myelolipoma (fig. 2a, b). 
Urinary epinephrine, metanephrine and vanillylmandelic acid were within normal lim-
its. A renal perfusion scan showed a small left kidney with reduced perfusion contributing 
22%  to  the  overall  tubular  function  without  obstructive  uropathy.  The  lower  extremity 
edema was partly ascribed to be due to inferior vena cava compression, and diuretics were 
decreased due to worsening renal function. Given the bradycardia and severe congestive 
heart failure, an electrophysiologist was consulted for evaluation and need for pacemaker 
implantation. Bradycardia was ascribed to be partly due to the Cushing reflex secondary to 
elevated blood pressure, and as the patient had no symptoms secondary to a low heart rate, 
pacemaker implantation was not advised. Despite maximum doses of clonidine, isosorbide, 
hydralazine, losartan and lisinopril, at best a moderate blood pressure control was achieved 
preoperatively.  
The patient was taken for surgical removal of the mass. During surgery, the mass was 
found to be soft, highly vascular but well encapsulated and attached only to the left adrenal 
gland via a small portion that was  resected along with the mass (fig. 3a,  b). There was 
minimal blood loss during the surgery, and the patient had an uneventful recovery in the 
postoperative period. A renal perfusion scan done 8 days after surgical removal showed 
36% contribution to the overall tubular function. Blood pressure control improved after 
surgery  and  the  patient  was  gradually  titrated  off  clonidine,  hydralazine  and  lisinopril. 
Bradycardia resolved with few episodes of atrial fibrillation with rapid ventricular response 
that were controlled with β-blockers and digoxin. The antihypertensive medications that the 
patient  was  discharged  on  were  carvedilol  40  mg,  valsartan  320  mg  and  isosorbide 
mononitrate 240 mg. 
Discussion 
Myelolipomas are composed of fat and hematopoietic tissue and are usually biochemi-
cally inactive. They are thought to arise from the reticuloendothelial cells of the adrenal 
gland in response to repeated stimulation by stress, inflammation and ACTH [11–13]. Both 
the adipose and the hematopoietic cells have been noted to have the same pattern of X-
chromosome inactivation and have been postulated to arise by clonal proliferation from a 
common  mesenchymal  stem  cell  [14].  Moreover,  the  chromosomal  translocation 
(3;21)(q25;p11)  has  been  detected  in  myelolipomas  in  patients  with  hematological 
malignancies, which has led to the speculation of bone marrow origin of these tumors [15]. 
Extra-adrenal  myelolipomas  have  been  documented  in  the  mediastinum,  lung,  thoracic 
spine, liver mesentery, spleen, kidney and pelvis [16–21]. They have been noted to be more 
common in women [22]. Extra-adrenal myelolipomas may mimic extramedullary hemato-
poietic  tumors  especially  since  bone  spicules  have  been  reported  [23].  Extramedullary 
hematopoietic tumors generally have a higher content of erythroid cells and less fat tissue 
compared  to  extra-adrenal  myelolipomas  which  have  a  relatively  higher  number  of 
lymphoid cells [24]. 
Adrenal myelolipomas are best imaged by CT due to the high negative attenuation value. 
However, calcification is seen in approximately 27% of the cases  and the presence of a  
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higher  proportion of  hematopoietic  tissues  may  mimic  an adrenal  adenoma  [4,  25,  26]. 
Ultrasonography is not a very useful diagnostic modality, especially if the tumors are smaller 
in size (<2 cm). An MRI has a similar diagnostic utility as a CT scan in adrenal myelolipomas 
with a high fat content [27]. The gold standard for diagnosis is tissue biopsy which typically 
shows hematopoietic cells admixed with mature adipose cells [6]. 
Adrenal myelolipomas can be associated with hyperaldosteronism, congenital adrenal 
hyperplasia and Cushing’s syndrome [28]. They are known to be biochemically inactive but a 
case of adrenal myelolipoma secreting cortisol has been reported [8]. Adrenal myelolipomas 
<5 cm are conservatively managed with sequential imaging, but larger masses are preferably 
resected due to the risk of hemorrhage [29]. Laparoscopic resection has been successfully 
used to reduce hospital stay and improve perioperative outcomes, but it is not preferable for 
tumors >10 cm or in tumors with infiltration or extensive adhesions [30, 31]. Our patient 
was fortunate not  to have any hemorrhagic  complications.  His clinical  presentation was 
compatible with symptoms related to mass effect of the giant myelolipoma, which resolved 
after surgical resection. 
Conclusion 
Adrenal myelolipomas are benign tumors with favorable outcomes when diagnosed in a 
timely manner. Their insidious clinical course becomes apparent only when mass effects are 
manifested in the form of an abdominal mass, flank pain, hypertension and pedal edema. It is 
important to differentiate them from other malignancies, such as liposarcoma, and to ensure 
that the myelolipoma is not biochemically active. Adequate follow-up of small masses and 
surgical  resection  of  large  masses  are  the  standard  of  care  which  provide  for  lesser 
morbidity and mortality. 
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Fig. 1. a CT scan of the abdominal mass seen in transverse view. b MRI scan of the abdominal mass seen in 
coronal view. 
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Fig. 2. a Low-power magnification of the biopsy showing capsule (red arrowhead), adrenal tissue (black 
arrowhead)  and  an  admixture  of  adipose  and  hematopoietic  cells.  b  High-power  magnification  of  the 
biopsy  showing  adipocytes  (black  arrowhead),  erythroid  precursors  (cyan  arrowhead),  lymphoid 
precursors (blue arrowhead) and megakaryocytes (green arrowhead). Bony spicules and sinusoids are 




Fig. 3. a Resected specimen showing a well-encapsulated tumor. b Resected specimen cut surface revealing 
adipose tissue with interspersed areas of hemorrhage. 
 